Astal Laboratories Ltd

Astal Laboratories Limited trading window closed from 01 October 2026 till 48 hours after the declaration of the unaudited financial results for the quarter & half year ended on 30 September 2026.

Governance and audit appointments

• Board approves M/s Avnesh Jain & Co. as Cost Auditor for FY 2026-27.
• Cost Auditor appointment effective 28 September 2026 for FY 2026-27.
• Board approves M/s Khandelwal & Co. as Secretarial Auditor for FY 2026-27.
• Board appoints Mr Balayogiswara Rao Pedinti as finance professional for FY 2026-27.
• Disclosures of relationships between directors for these appointments Not Applicable.

Company Secretary appointment

• Appointment of Kedia as Company Secretary of Astal Laboratories Limited effective 28 September 2026.

AGM Details

• Date, time and mode: 29 September 2026, 1:30 PM IST via VC/OAVM.

Resolutions

• Ordinary: Adopt standalone financial statements for the year ended 31 March 2026.
• Ordinary: Adopt consolidated financial statements for the year ended 31 March 2026.
• Ordinary: Re-appointment of Maggidi Venkatesh, Non-Executive Director, by rotation.

Director Changes

• Maggidi Venkatesh re-appointed as Non-Executive Director by rotation.

Voting Details

• Mode of voting: E-Voting for all resolutions.
• Voting results to be disseminated within 48 hours.

Code type and regulation

• Code of Conduct under SEBI PIT Regulations, 2015 governs insider trading.

Promoter disclosures received

• Promoter ACESO RESEARCH LABS LLP submitted Form C for share purchases (10 Sep 2026).

Declaration filed

• Declaration under Regulation 7(2) for purchase of equity shares enclosed.

Recordkeeping and reporting

• Disclosures recorded by Corporate Secretary and shared with BSE.

Roles and responsibilities

• Company Secretary & Compliance Officer oversee insider-trading disclosures.

AGM notice and report access

• AGM 33rd scheduled for Sep 29, 2026 at 1:30 PM IST via VC/OAVM.
• Annual Report FY2025-26 and AGM Notice accessible on astallabs.com.
• Book closure from Sep 23 to Sep 29, 2026.
• Voting cut-off date Sep 22, 2026.
• e-voting opens Sep 26, 2026; ends Sep 29, 2026 at 5:00 PM.
• Notice accessible via provided web link and QR code.
• Annual Report available on CDSL and BSE websites.
• Physical copies available on request to investor relations.
• KYC update reminder for SEBI circular; PAN, contact, bank details required.
• Dematerialization of physical securities urged; update with DP or RTA.

AGM Details

• AGM scheduled for 29 September 2026 at 01:30 PM.
• Mode: VC/OAVM.
• Record date: 22 September 2026.
• Register of Members closed 23-29 September 2026.

Key Ordinary Resolutions

• Adopt standalone financial statements for FY2025-26.
• Adopt consolidated financial statements for FY2025-26.
• Re-appointment of director retiring by rotation.

Director Changes

• Director retire-by-rotation; eligible for re-appointment.

Financial highlights

• Standalone revenue from operations: ₹15,599.53 lakh for FY2025-26.
• Standalone PAT: ₹811.55 lakh.
• Consolidated revenue from operations: ₹25,014.81 lakh.
• Consolidated PAT: ₹1,470.94 lakh.
• Revenue growth (Standalone YoY): 142.88%.
• Standalone PAT YoY: -9.07%.
• Dividend declared for FY2025-26: none.
• Consolidated results include Sriven Pharmachem from 14-Jan-2026.

Acquisition & growth

• Sriven Pharmachem India Pvt Ltd acquired; 100% stake.
• Acquisition date: 14-Jan-2026.
• Goodwill recognized: ₹20,320.17 lakh.
• Consideration: ₹27,716.95 lakh; Net assets: ₹7,396.98 lakh.
• Equity issued: 3,04,25,632 shares at ₹81 premium.
• Warrants converted: 19,59,930 shares; ₹587.98 lakh received.
• Equity share capital increased to ₹4,223.12 lakh.
• Acquiree wholly owned; consolidation from acquisition date.

Capital structure & liquidity

• Standalone long-term borrowings: ₹36.59 lakh; current ₹1,159.20 lakh.
• Consolidated long-term borrowings: ₹1,864.15 lakh; current ₹3,044.10 lakh.
• Total borrowings: standalone ₹1,195.78 lakh; consolidated ₹4,908.25 lakh.
• Standalone cash and cash equivalents: ₹69.60 lakh.
• Consolidated cash and cash equivalents: ₹70.27 lakh.
• Equity capital stands at ₹4,223.12 lakh.

Subsidiary & consolidation

• Sriven Pharmachem India Pvt Ltd is a wholly owned subsidiary.
• Consolidated FS include Sriven from 14-Jan-2026.
• Goodwill from acquisition: ₹20,320.17 lakh.
• Acquisition comprised 30,458,187 equity shares; 3,04,25,632 via swap.
• Consolidation eliminates intragroup balances.

Governance & CSR

• Board: 7 directors; 4 independent; one Whole Time Director.
• Independent Directors meeting on 14-Feb-2026.
• EPS: standalone basic ₹4.76; diluted ₹4.31.
• EPS: consolidated basic ₹8.62; diluted ₹7.81.
• CSR spend ₹8.73 lakh; average net profit ₹43.65 crore.
• Dividend policy: no dividend.

Outlook & risks

• Outlook remains positive; focus on API manufacturing and R&D.
• Strategic acquisitions to expand global footprint.
• Risks include regulatory compliance, supply chain, pricing, and FX movements.

Meeting Details

• Date: 04 September 2026.
• Time: Not disclosed.
• Location: Corporate office, The Platina, Kondapur, Telangana.

Key Agenda Items

• To consider and approve the Notice of the 33rd AGM and fix date, time and venue.
• To approve Board Report along with all annexures for financial year ended March 31 2026.
• To appoint Scrutinizer to scrutinize voting at AGM and remote e-voting.

Other Notes

• Trading window closure periods are not specified.